Novo Nordisk Shares Likely to Fall at Open, but Less than in U.S. Session

Dow Jones08-05

0700 GMT - Novo Nordisk shares are expected to come under pressure in Europe this morning, but to a lesser degree than the 6% drop in U.S. trading yesterday, Jyske Bank's Henrik Hallengreen Laustsen writes. The company significantly beat estimates in the second quarter and raised its outlook more than expected. Sales and earnings were both above expectations in the quarter, driven by Ozempic, while the Wegovy pill performed largely as forecast. Consensus estimates might be increased by approximately 3% if expectations are raised to the midpoint of the new guidance, he adds. However, a study of its CagriSema drug showed that the product is no better than Eli Lilly's Mounjaro in diabetes, which could pressure CagriSema estimates and thus Novo's long-term growth profile, which remains one of investors' biggest concerns.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment